Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2530369 | 0.85 | HSD11B1 (0.45) | RXFP1TRPV1KDM4ETSHRALDH1A1 | |
| SCHEMBL2525410 | 0.85 | RXFP1 (0.49) | RXFP1KDM4ETSHRALDH1A1HPGD | |
| SCHEMBL2525114 | 0.79 | KDM4E (0.50) | KDM4ETSHRALDH1A1HPGDMEN1 | |
| SCHEMBL5466265 | 0.79 | DHFR (0.42) | RXFP1TRPV1KDM4EALDH1A1MEN1 | |
| SCHEMBL2524599 | 0.79 | MAPT (0.41) | RXFP1TSHRALDH1A1AOC3SMN1; SMN2 | |
| SCHEMBL2530699 | 0.79 | TRPV1 (0.51) | TRPV1NR1H2NR1H3AOC3ADRB1 | |
| SCHEMBL2525372 | 0.78 | KDM4E (0.46) | RXFP1KDM4ETSHRALDH1A1HPGD | |
| SCHEMBL2529108 | 0.78 | MAPT (0.60) | RXFP1KDM4ETSHRALDH1A1HPGD | |
| SCHEMBL2528532 | 0.77 | AR (0.46) | RXFP1KDM4ETSHRALDH1A1HPGD | |
| SCHEMBL2530279 | 0.77 | AR (0.46) | RXFP1KDM4ETSHRALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | GRUENENTHAL GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | GRUENENTHAL GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | GRUENENTHAL GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-8710233-B2 | Vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations | GRUENENTHAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8710233-B2 | Vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations | GRUENENTHAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8710233-B2 | Vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations | GRUENENTHAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| EP-1940821-B1 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| EP-1940821-B1 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| EP-2388258-A1 | Novel vanilloid receptor ligands and their use for producing medicaments | Grünenthal GmbH (DE) | 2011-11-23 | — | — | EP | disclosed |
| US-8038010-B1 | Single piece edge protector for curved objects | ILLINOIS TOOL WORKS INC. (US) | 2011-10-18 | — | — | US | disclosed |
| EP-1940821-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | Grünenthal GmbH (DE) | 2008-07-09 | — | — | EP | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| WO-2007045462-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | Grünenthal GmbH (DE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045462-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | Grünenthal GmbH (DE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | TRPV1, TRPV5, TRPV2 | RXFP1 810/4885PIK3CD 2771/4885PIK3R1 2530/4885 |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | TRPV1, TRPV5, TRPV2 | RXFP1 810/4885PIK3CD 2771/4885PIK3R1 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.